Allogene Therapeutics, Inc. (ALLO) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 169 institutional investors hold a position in Allogene Therapeutics, Inc. (NASDAQ:ALLO).

• The percentage of Allogene Therapeutics owned by institutions changed from 79.4% in June 2025 to 72.9% in September 2025, marking a slight down trend.
• On a quarter-over-quarter basis, institutional holdings shifted by 2.26%, with a year-over-year an increase of 9.74% in the count of filers.
• A review of institutional activity for Allogene Therapeutics shows 87 of 169 filers increasing their positions, while 41 reduced their stake, and 41 remained unchanged.
• The total number of shares held by institutions in Allogene Therapeutics increased to 161.72Mn as of September 2025, a net change of up by 3.57Mn shares quarter on quarter, and up 134.62K shares year over year.
• With 22.03Mn shares, PFIZER INC commands the largest institutional position in Allogene Therapeutics as of September 30, 2025, equating to 9.93% of the company.
• Among the most significant buyers of Allogene Therapeutics during September 2025 were CITADEL ADVISORS LLC (3.77Mn), MILLENNIUM MANAGEMENT LLC (1.89Mn), AQR CAPITAL MANAGEMENT LLC (1.77Mn), TWO SIGMA INVESTMENTS, LP (1.77Mn), UBS Group AG (1.53Mn).
• Leading sellers of Allogene Therapeutics stock in September 2025 included Lynx1 Capital Management LP (10.51Mn), GOLDMAN SACHS GROUP INC (4.30Mn), DIMENSIONAL FUND ADVISORS LP (645.67K), BlackRock, Inc. (382.73K), PRICE T ROWE ASSOCIATES INC /MD/ (353.40K).
• The top 10 institutional holders of Allogene Therapeutics for the quarter ending September 2025 included PFIZER INC (22.03Mn), TPG GP A, LLC (18.72Mn), BlackRock, Inc. (17.51Mn), CITADEL ADVISORS LLC (13.97Mn), VANGUARD GROUP INC (9.02Mn), PRIMECAP MANAGEMENT CO/CA/ (7.08Mn), Woodline Partners LP (4.36Mn), Frazier Life Sciences Management, L.P. (3.87Mn), GEODE CAPITAL MANAGEMENT, LLC (3.83Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.68Mn).